Zai Lab (ZLAB) said late Wednesday the US Food and Drug Administration has granted orphan drug designation to ZL-1310 for the treatment of small cell lung cancer following data from an ongoing phase 1a/1b study.
ZL-1310 will be eligible for certain development incentives, including tax credits for certain clinical trials and the potential to receive a seven-year US market exclusivity period upon product approval, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments